$599

Zealand Q1 ’19 Earnings Update

Zealand hosted its Q1 ’19 earnings call and provided updates to its diabetes business including dasiglucagon (hypoglycemia rescue, congenital hyperinsulinism, and bi-hormonal closed-loop) and its GLP-1/GCG dual agonist with Boehringer Ingelheim. Recall, Zealand recently disclosed that its dasiglucagon hypoglycemia rescue filing has been delayed to early 2020. Below, FENIX provides highlights and insights from the call.

This content is for Read Less members only.
Register
Already a member? Log in here